Reduced-intensity stem cell transplant for high-risk solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a less intense type of bone marrow (stem cell) transplant from a partly matched family donor for people with high-risk solid tumors. It aims to lower treatment intensity while still using the donor’s immune system to help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 1 and 50 years old
- You have a “high-risk” solid tumor diagnosis with a less than 10% expected chance of survival
- A related donor can be found who is a close partial match for your immune tissue type (HLA) and shares at least one matching set across key HLA genes
- You’ve had standard treatment for your cancer, and either it didn’t work well enough, it came back, or your cancer situation fits the trial’s high-risk categories
- Your organs (heart, liver, kidneys, and lungs) work well enough for transplant
- You can agree to the treatment plan and you’re willing to take part in all stages; pregnant people can’t enroll
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving donor lymphocyte (immune) infusions after a bone marrow transplant for people with high-risk blood cancers. The goal is to help the immune system better fight the cancer and improve outcomes after transplant.
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a special stem cell transplant from a half-matched family donor, designed to reduce rejection and infection risk. It may include a targeted drug (blinatumomab) to help kill remaining cancer cells.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Hear when a new Refractory and/or Relapsed Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.